Nicaraven

DB06397ExperimentalSmall molecule

Investigated for use/treatment in cerebrovascular disease (unspecified).

Mechanism: Nicaraven is presently being developed for the treatment of cerebral stroke including subarachnoid hemorrhage. This drug is promising because some data suggest it to have an ability to scavenge the hydroxyl radical under physiological conditions in vivo, while it also has a high permeability through the blood brain barrier.
Curator reviewed
Primary indication: Investigated for use/treatment in cerebrovascular disease (unspecified).Curator reviewed
Formula / weight: C₁₅H₁₆N₄O₂ · 284.319 g/mol (avg)

Resolves to

Compound

Structure

InChIKeyKTXBOOWDLPUROC-UHFFFAOYSA-NSMILESCC(CNC(=O)C1=CC=CN=C1)NC(=O)C1=CC=CN=C1

Targets

What you can answer from here — as of April 02, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Nicaraven, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.